Similar articles

• Dihydroergocryptine: a "pseudo-irreversible" alpha-adrenergic antagonist in the guinea pig vas deferens.

  Wilberding CA, Marks BH. Wilberding CA, et al. Res Commun Chem Pathol Pharmacol. 1981 Mar;31(3):387-401. Res Commun Chem Pathol Pharmacol. 1981. PMID: 6265988
• [3H]Dihydroergocryptine binding to alpha adrenergic receptors in canine aortic membranes.

  Tsai BS, Lefkowitz RJ. Tsai BS, et al. J Pharmacol Exp Ther. 1978 Mar;204(3):606-14. J Pharmacol Exp Ther. 1978. PMID: 24730 No abstract available.
• Occupancy of alpha 1-adrenergic receptors and contraction of rat vas deferens.

  Minneman KP, Fox AW, Abel PW. Minneman KP, et al. Mol Pharmacol. 1983 Mar;23(2):359-68. Mol Pharmacol. 1983. PMID: 6300645
• Pharmacological characterization of receptors: its relation to radioligand-binding studies.

  Furchgott RF. Furchgott RF. Fed Proc. 1978 Feb;37(2):115-20. Fed Proc. 1978. PMID: 203488 Review. No abstract available.
• Radioligand binding studies of adrenergic receptors: new insights into molecular and physiological regulation.

  Hoffman BB, Lefkowitz RJ. Hoffman BB, et al. Annu Rev Pharmacol Toxicol. 1980;20:581-608. doi: 10.1146/annurev.pa.20.040180.003053. Annu Rev Pharmacol Toxicol. 1980. PMID: 6247962 Review. No abstract available.